Nov 19, 2017
Prima BioMed Changes its Name to Immutep Ltd
Nov 14, 2017
Eftilagimod Alpha (LAG-3Ig or IMP321) Pre-IND Meeting with the FDA
Nov 07, 2017
New Eftilagimod Alpha (LAG-3Ig or IMP321) Data for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting
Oct 30, 2017
Dr. Frédéric Triebel Presented at the World Immunotherapy Congress 2017
Oct 18, 2017
Dr. Frédéric Triebel presenting at the World Immunotherapy Congress 2017
Oct 16, 2017
IMP321 New Data Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting
Sep 07, 2017
Prima Secures Japanese Patent Grant for IMP731 Antibody
Sep 05, 2017
Prima Secures Japanese Patent Grant for Lead Product IMP321 in Infectious Disease
Aug 29, 2017
Prima BioMed and Monash University Receive Funding Grant for LAG-3 Research Project
Aug 19, 2017
Prima BioMed Appoints Non-Executive Director to the Board
Aug 14, 2017
Prima BioMed Receives A$1.3 Million Tax Refund from French Government
Jul 18, 2017
Financial Update 2H17
